145 related articles for article (PubMed ID: 16886660)
1. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway.
Moreno J; Krishnan AV; Peehl DM; Feldman D
Anticancer Res; 2006; 26(4A):2525-30. PubMed ID: 16886660
[TBL] [Abstract][Full Text] [Related]
2. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells.
Moreno J; Krishnan AV; Swami S; Nonn L; Peehl DM; Feldman D
Cancer Res; 2005 Sep; 65(17):7917-25. PubMed ID: 16140963
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer.
Moreno J; Krishnan AV; Feldman D
J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):31-6. PubMed ID: 16024246
[TBL] [Abstract][Full Text] [Related]
4. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity.
Krishnan AV; Moreno J; Nonn L; Swami S; Peehl DM; Feldman D
J Bone Miner Res; 2007 Dec; 22 Suppl 2():V74-80. PubMed ID: 18290727
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment.
Krishnan AV; Feldman D
Endocr Relat Cancer; 2010 Mar; 17(1):R19-38. PubMed ID: 19926709
[TBL] [Abstract][Full Text] [Related]
6. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer.
Krishnan AV; Moreno J; Nonn L; Malloy P; Swami S; Peng L; Peehl DM; Feldman D
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):694-702. PubMed ID: 17229571
[TBL] [Abstract][Full Text] [Related]
7. Expression of prostaglandin metabolising enzymes COX-2 and 15-PGDH and VDR in human granulosa cells.
Thill M; Becker S; Fischer D; Cordes T; Hornemann A; Diedrich K; Salehin D; Friedrich M
Anticancer Res; 2009 Sep; 29(9):3611-8. PubMed ID: 19667156
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines.
Thill M; Fischer D; Becker S; Cordes T; Dittmer C; Diedrich K; Salehin D; Friedrich M
Anticancer Res; 2009 Sep; 29(9):3619-25. PubMed ID: 19667157
[TBL] [Abstract][Full Text] [Related]
9. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer.
Swami S; Krishnan AV; Moreno J; Bhattacharyya RB; Peehl DM; Feldman D
J Nutr; 2007 Jan; 137(1 Suppl):205S-210S. PubMed ID: 17182827
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase.
Wakimoto N; Wolf I; Yin D; O'Kelly J; Akagi T; Abramovitz L; Black KL; Tai HH; Koeffler HP
Cancer Res; 2008 Sep; 68(17):6978-86. PubMed ID: 18757412
[TBL] [Abstract][Full Text] [Related]
11. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
Gavrilov V; Steiner M; Shany S
Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
[TBL] [Abstract][Full Text] [Related]
12. Influence of calcitriol on prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cell lines.
Thill M; Cordes T; Hoellen F; Becker S; Dittmer C; Kümmel S; Salehin D; Friedrich M; Diedrich K; Köster F
Anticancer Res; 2012 Jan; 32(1):359-65. PubMed ID: 22213327
[TBL] [Abstract][Full Text] [Related]
13. Correlation of prostaglandin metabolizing enzymes and serum PGE2 levels with vitamin D receptor and serum 25(OH)2D3 levels in breast and ovarian cancer.
Cordes T; Hoellen F; Dittmer C; Salehin D; Kümmel S; Friedrich M; Köster F; Becker S; Diedrich K; Thill M
Anticancer Res; 2012 Jan; 32(1):351-7. PubMed ID: 22213326
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients.
Swami S; Krishnan AV; Moreno J; Bhattacharyya RS; Gardner C; Brooks JD; Peehl DM; Feldman D
Int J Cancer; 2009 May; 124(9):2050-9. PubMed ID: 19127598
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer.
Krishnan AV; Srinivas S; Feldman D
Dermatoendocrinol; 2009 Jan; 1(1):7-11. PubMed ID: 20046582
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin metabolising enzymes and PGE2 are inversely correlated with vitamin D receptor and 25(OH)2D3 in breast cancer.
Thill M; Fischer D; Hoellen F; Kelling K; Dittmer C; Landt S; Salehin D; Diedrich K; Friedrich M; Becker S
Anticancer Res; 2010 May; 30(5):1673-9. PubMed ID: 20592360
[TBL] [Abstract][Full Text] [Related]
17. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Quidville V; Segond N; Lausson S; Frenkian M; Cohen R; Jullienne A
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):14-30. PubMed ID: 16997128
[TBL] [Abstract][Full Text] [Related]
18. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis.
Bao BY; Yao J; Lee YF
Carcinogenesis; 2006 Sep; 27(9):1883-93. PubMed ID: 16624828
[TBL] [Abstract][Full Text] [Related]
19. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis.
Peehl DM; Shinghal R; Nonn L; Seto E; Krishnan AV; Brooks JD; Feldman D
J Steroid Biochem Mol Biol; 2004 Oct; 92(3):131-41. PubMed ID: 15555907
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug.
Wang YR; Wigington DP; Strugnell SA; Knutson JC
Anticancer Res; 2005; 25(6B):4333-9. PubMed ID: 16309237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
